Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1994 | Methylene-Blue Photodisinfection Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is a multicenter, randomized, open-label, controlled trial to evaluate the effectiveness and safety of Rhea Health Tone® as add-on therapy in hospitalized adults with COVID-19. The study is a multi-center trial that will be conducted in up to approximately 2 sites nationally. New sites may be added as needed after appropriate assessment. Interim monitoring will be conducted to evaluate the arms and for safety and effectiveness. Any change would be accompanied by updated sample size. Subjects will be assessed while hospitalized. All subjects will undergo a series of laboratory (inflammatory biomarkers (IL-6, hs-CRP, IFNγ), SGOT, SGPT and Creatinine, conversion rate by PCR, QTc prolongation by ECG, chest X-ray), clinical (clinical assessment, vital sign, concomitant medication, other medical conditions) and safety assessment (serious adverse event). Randomization will be performed 1:1 for each arm. Arm 1 = Standard of Care (SoC) alone, arm 2 = SoC + Rhea Health Tone®.
Description: Total days the subjects were hospitalized
Measure: Length of stay Time: From the date of randomization until the date of first documented subject discharge or death from any cause, assessed up to 10 daysDescription: Total days of oxygen supplementation
Measure: Duration of oxygenation Time: From the date of randomization until the date of first documented subject discharge or death from any cause, assessed up to 10 daysDescription: Total days of receiving ventilation
Measure: Duration of ventilation Time: From the date of randomization until the date of first documented subject discharge or death from any cause, assessed up to 10 daysDescription: Total days of conversion rate from positive to negative by PCR result
Measure: PCR conversion Time: Will be examined at days 1st , 7th, and 10th.Description: IL-6 (pg/mL)
Measure: Inflammatory biomarkers 1 Time: Will be examined at days 1st and 10th.Description: hs-CRP (mg/L)
Measure: Inflammatory biomarkers 2 Time: Will be examined at days 1st and 10th.Description: IFNγ (pg/mL)
Measure: Inflammatory biomarkers 3 Time: Will be examined at days 1st and 10th.Description: Daily measurement of temperature, heart rate, respiratory rate, blood pressure, oxygen saturation, capillary filling time >2 seconds
Measure: Percentage of improvement of subjects' clinical status Time: From the date of randomization until the date of first documented subject discharge or death from any cause, assessed up to 10 daysDescription: Percentage of improvement of subjects based on chest X-ray
Measure: X-Ray Time: From the date of informed consent signed by subject, until the date of first documented subject discharge or death from any cause, assessed up to 10 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports